Recent Advances in Liquid Biopsy Based on Circulating Tumor DNA

Sakuma, Yu; Fujii, Kenichi; Han, Jiayan; Takahashi, Ryou‐u

doi:10.3390/jcm8111957

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LSLC-specific mutation signatures that are carried by LSLC-EXO may serve as clinical liquid biopsy biomarkers for cancer diagnostics and prognostics 35 . Although numerous studies showed that cancer specific mutations could be detected in circulating tumor DNA 36 – 38 , few studies have explored the signatures of exosomal genetic variants in cancer. To examine whether genetic variants in cancer cells at RNA level were also present in their derived exosomes, we performed variant calling analysis by Genome Analysis Tool Kit (GATK) using our Ribo-zero RNA-seq data.…”

Section: Resultsmentioning

confidence: 99%

Dissecting the multi-omics atlas of the exosomes released by human lung adenocarcinoma stem-like cells

et al. 2021

View full text Add to dashboard Cite

Lung adenocarcinoma is heterogeneous and hierarchically organized, with a subpopulation of stem-like cells (CSCs) that reside at the apex of the hierarchy, in which exosomes act as important mediators by transporting specific molecules among different cell populations. Although there have been numerous studies on tumor exosomes, the constituents and functional properties of CSC-derived exosomes are still poorly characterized. Here we present a detail transcriptome and proteome atlas of the exosomes released by human lung adenocarcinoma stem-like cells (LSLCs). The transcriptome analysis indicates the specific patterns of exosomal constituents, including the fragmentation of transcripts and the low-level presence of circular RNAs, and identifies multiple exosomal-enriched mRNAs and lncRNAs. Integrative analysis of transcriptome and proteome data reveals the diverse functions of exosomal-enriched RNAs and proteins, many of which are associated with tumorigenesis. Importantly, several LSLC markers we identified are highly expressed in LSLC-derived exosomes and associate with poor survival, which may serve as promising liquid biopsy biomarkers for lung adenocarcinoma diagnosis. Our study provides a resource for the future elucidation of the functions of tumor-derived exosomes and their regulatory mechanisms in mediating lung cancer development.

show abstract

Section: Resultsmentioning

confidence: 99%

Dissecting the multi-omics atlas of the exosomes released by human lung adenocarcinoma stem-like cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, liquid biopsy concerning breast ductal fluid, breast milk, seminal fluid, cervical and vaginal secretions, and uterine/utero-tubular lavage can improve the management of various genital cancers of men as well as women [ 31 , 32 , 33 , 34 , 35 , 36 ]. Several other liquid biopsy samples including tear fluid, sweat, wound efflux, amniotic fluid or bronchoalveolar and peritoneal lavage can also provide benefits for the patient and healthcare at large [ 7 , 9 , 37 , 38 ]. Therefore, an increasing evidence shows that various types of liquid biopsy, illustrated in Figure 1 , have the potential in cancer diagnostics, disease stratification, and monitoring of response to therapeutic interventions and could replace invasive tissue biopsy.…”

Section: Liquid Biopsy Classificationmentioning

confidence: 99%

“…Traditionally strong is an application of biomarkers related to the blood-based biopsy. However, increasing evidence demonstrates that the application of complementary types of liquid biopsy is crucial for the overall quality of diagnostics [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. The current article highlights very recent progress made in the area and provides prominent examples of a spectrum of liquid biopsy approaches with great potential to benefit several patient cohorts and to improve overall healthcare quality.…”

Section: Introductionmentioning

confidence: 99%

Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management

Líšková

Samec

Koklesová

et al. 2020

JCM

View full text Add to dashboard Cite

One in every four deaths is due to cancer in Europe. In view of its increasing incidence, cancer became the leading cause of death and disease burden in Denmark, France, the Netherlands, and the UK. Without essential improvements in cancer prevention, an additional 775,000 cases of annual incidence have been prognosed until 2040. Between 1995 and 2018, the direct costs of cancer doubled from EUR 52 billion to EUR 103 billion in Europe, and per capita health spending on cancer increased by 86% from EUR 105 to EUR 195 in general, whereby Austria, Germany, Switzerland, Benelux, and France spend the most on cancer care compared to other European countries. In view of the consequent severe socio-economic burden on society, the paradigm change from a reactive to a predictive, preventive, and personalized medical approach in the overall cancer management is essential. Concepts of predictive, preventive, and personalized medicine (3PM) demonstrate a great potential to revise the above presented trends and to implement cost-effective healthcare that benefits the patient and society as a whole. At any stage, application of early and predictive diagnostics, targeted prevention, and personalization of medical services are basic pillars making 3PM particularly attractive for the patients as well as ethical and cost-effective healthcare. Optimal 3PM approach requires novel instruments such as well-designed liquid biopsy application. This review article highlights current achievements and details liquid biopsy approaches specifically in cancer management. 3PM-relevant expert recommendations are provided.

show abstract

Liquid biopsy: the current state of the issue

Pasechnikova

Bodnya

Sharov³

et al. 2021

Innovacionnaâ medicina Kubani

View full text Add to dashboard Cite

Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic changes. This work included a literature review of current scientific publications on liquid biopsy techniques indexed in PubMed.Objective The aim of the study was to evaluate the efficacy and peculiarities of this technique in comparison with standard methods of morphological verification of oncological diseases, as well as the feasibility of its use in clinical practice. Compared to tissue biopsy LB has the following advantages: simplicity and speed of examination, easy repeatability and low invasiveness, possibility of dynamic monitoring of tumor progression – general clonal transformation as well as the appearance of resistance to treatment. The disadvantages of this method include low sensitivity, difficulty in proper interpretation of biomarkers and determination of their specificity, high risk of false positive and false negative results due to the presence of dormant tumor cells.Conclusion Currently, liquid biopsy analysis in clinical practice requires standardization and continuous validation.

show abstract

Recent Advances in Liquid Biopsy Based on Circulating Tumor DNA

Abstract: Many types of cells secrete DNA, RNA, and proteins through microvesicles, such as exosomes and apoptotic bodies, for the purpose of extracellular communication [...]

Cited by 3 publications

References 5 publications

Dissecting the multi-omics atlas of the exosomes released by human lung adenocarcinoma stem-like cells

Dissecting the multi-omics atlas of the exosomes released by human lung adenocarcinoma stem-like cells

Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management

Liquid biopsy: the current state of the issue

Contact Info

Product

Resources

About